PBAC's latest decision on Gemcitabine: Recommended (2025). Considered for Multiple oncology indications including locally advanced or metastatic non-small cell lung cancer, adenocarcinoma, pancreatic cancer, bladder cancer, breast cancer (in combination with paclitaxel), and ovarian cancer (in combination with carboplatin).
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients with oncology indications approved for gemcitabine (locally advanced or metastatic non-small cell lung cancer, adenocarcinoma, pancreatic cancer, bladder cancer, breast cancer, and ovarian cancer) treated in public or private hospitals.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
DBL Gemcitabine (1 g/26.3 mL injection and 2 g/52.6 mL injection)
Economic model
Cost-minimisation
Eligible patients/year
64,879
ICER note
Cost-minimisation analysis; no ICER calculated as this is a substitutional listing with equivalent efficacy.